vs
Apellis Pharmaceuticals, Inc.（APLS）与Tenable Holdings, Inc.（TENB）财务数据对比。点击上方公司名可切换其他公司
Tenable Holdings, Inc.的季度营收约是Apellis Pharmaceuticals, Inc.的1.3倍（$262.1M vs $199.9M），Tenable Holdings, Inc.净利率更高（0.5% vs -29.5%，领先30.0%），Tenable Holdings, Inc.同比增速更快（9.6% vs -5.9%），Tenable Holdings, Inc.自由现金流更多（$82.6M vs $-14.3M），过去两年Tenable Holdings, Inc.的营收复合增速更高（8.8% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Tenable Holdings, Inc.是总部位于美国马里兰州哥伦比亚市的网络安全企业，旗下1998年推出的漏洞扫描软件Nessus是全球网络安全行业应用最广泛的漏洞评估解决方案之一。截至2023年12月31日，公司拥有约4.4万家客户，其中包括65%的财富500强企业。
APLS vs TENB — 直观对比
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $262.1M |
| 净利润 | $-59.0M | $1.4M |
| 毛利率 | — | 78.4% |
| 营业利润率 | -25.6% | 25.0% |
| 净利率 | -29.5% | 0.5% |
| 营收同比 | -5.9% | 9.6% |
| 净利润同比 | -62.2% | — |
| 每股收益（稀释后） | $-0.40 | $0.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q1 26 | — | $262.1M | ||
| Q4 25 | $199.9M | $260.5M | ||
| Q3 25 | $458.6M | $252.4M | ||
| Q2 25 | $178.5M | $247.3M | ||
| Q1 25 | $166.8M | $239.1M | ||
| Q4 24 | $212.5M | $235.7M | ||
| Q3 24 | $196.8M | $227.1M | ||
| Q2 24 | $199.7M | $221.2M |
| Q1 26 | — | $1.4M | ||
| Q4 25 | $-59.0M | $-737.0K | ||
| Q3 25 | $215.7M | $2.3M | ||
| Q2 25 | $-42.2M | $-14.7M | ||
| Q1 25 | $-92.2M | $-22.9M | ||
| Q4 24 | $-36.4M | $1.9M | ||
| Q3 24 | $-57.4M | $-9.2M | ||
| Q2 24 | $-37.7M | $-14.6M |
| Q1 26 | — | 78.4% | ||
| Q4 25 | — | 78.8% | ||
| Q3 25 | — | 77.5% | ||
| Q2 25 | — | 78.0% | ||
| Q1 25 | — | 78.1% | ||
| Q4 24 | — | 78.2% | ||
| Q3 24 | — | 77.8% | ||
| Q2 24 | — | 77.9% |
| Q1 26 | — | 25.0% | ||
| Q4 25 | -25.6% | 3.4% | ||
| Q3 25 | 48.7% | 2.8% | ||
| Q2 25 | -18.6% | -3.0% | ||
| Q1 25 | -50.0% | -7.4% | ||
| Q4 24 | -12.3% | 5.5% | ||
| Q3 24 | -24.0% | -0.9% | ||
| Q2 24 | -14.7% | -4.0% |
| Q1 26 | — | 0.5% | ||
| Q4 25 | -29.5% | -0.3% | ||
| Q3 25 | 47.0% | 0.9% | ||
| Q2 25 | -23.6% | -5.9% | ||
| Q1 25 | -55.3% | -9.6% | ||
| Q4 24 | -17.1% | 0.8% | ||
| Q3 24 | -29.2% | -4.1% | ||
| Q2 24 | -18.9% | -6.6% |
| Q1 26 | — | $0.01 | ||
| Q4 25 | $-0.40 | $-0.01 | ||
| Q3 25 | $1.67 | $0.02 | ||
| Q2 25 | $-0.33 | $-0.12 | ||
| Q1 25 | $-0.74 | $-0.19 | ||
| Q4 24 | $-0.30 | $0.01 | ||
| Q3 24 | $-0.46 | $-0.08 | ||
| Q2 24 | $-0.30 | $-0.12 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $360.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $248.2M |
| 总资产 | $1.1B | $1.6B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q1 26 | — | $360.3M | ||
| Q4 25 | $466.2M | $402.2M | ||
| Q3 25 | $479.2M | $383.6M | ||
| Q2 25 | $370.0M | $386.5M | ||
| Q1 25 | $358.4M | $460.3M | ||
| Q4 24 | $411.3M | $577.2M | ||
| Q3 24 | $396.9M | $548.4M | ||
| Q2 24 | $360.1M | $487.0M |
| Q1 26 | — | $248.2M | ||
| Q4 25 | $370.1M | $326.4M | ||
| Q3 25 | $401.2M | $344.4M | ||
| Q2 25 | $156.3M | $350.7M | ||
| Q1 25 | $164.2M | $383.2M | ||
| Q4 24 | $228.5M | $400.0M | ||
| Q3 24 | $237.1M | $404.6M | ||
| Q2 24 | $264.3M | $363.6M |
| Q1 26 | — | $1.6B | ||
| Q4 25 | $1.1B | $1.7B | ||
| Q3 25 | $1.1B | $1.7B | ||
| Q2 25 | $821.4M | $1.7B | ||
| Q1 25 | $807.3M | $1.7B | ||
| Q4 24 | $885.1M | $1.7B | ||
| Q3 24 | $901.9M | $1.6B | ||
| Q2 24 | $904.5M | $1.6B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $88.0M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $82.6M |
| 自由现金流率自由现金流/营收 | -7.1% | 31.5% |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | 62.21× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $256.4M |
8季度趋势，按日历期对齐
| Q1 26 | — | $88.0M | ||
| Q4 25 | $-14.2M | $83.0M | ||
| Q3 25 | $108.5M | $53.9M | ||
| Q2 25 | $4.4M | $42.5M | ||
| Q1 25 | $-53.4M | $87.4M | ||
| Q4 24 | $19.4M | $81.1M | ||
| Q3 24 | $34.1M | $54.6M | ||
| Q2 24 | $-8.3M | $31.4M |
| Q1 26 | — | $82.6M | ||
| Q4 25 | $-14.3M | $82.7M | ||
| Q3 25 | $108.3M | $53.0M | ||
| Q2 25 | $4.4M | $38.1M | ||
| Q1 25 | $-53.4M | $80.9M | ||
| Q4 24 | $19.3M | $78.8M | ||
| Q3 24 | — | $53.9M | ||
| Q2 24 | $-8.4M | $30.9M |
| Q1 26 | — | 31.5% | ||
| Q4 25 | -7.1% | 31.7% | ||
| Q3 25 | 23.6% | 21.0% | ||
| Q2 25 | 2.5% | 15.4% | ||
| Q1 25 | -32.0% | 33.8% | ||
| Q4 24 | 9.1% | 33.4% | ||
| Q3 24 | — | 23.7% | ||
| Q2 24 | -4.2% | 14.0% |
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 0.1% | ||
| Q3 25 | 0.0% | 0.3% | ||
| Q2 25 | 0.0% | 1.8% | ||
| Q1 25 | 0.0% | 2.7% | ||
| Q4 24 | 0.0% | 1.0% | ||
| Q3 24 | 0.0% | 0.3% | ||
| Q2 24 | 0.0% | 0.2% |
| Q1 26 | — | 62.21× | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | 23.83× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 43.43× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
TENB
| Subscription revenue | $243.2M | 93% |
| Perpetual license and maintenance revenue | $10.2M | 4% |
| Other | $8.7M | 3% |
